Want to see HK:1110 full AI Analyst Report?
1110 Stock Chart & Stats
HK$0.53
>-HK$0.01(-1.12%)
At close: 4:00 PM EST
HK$0.53
>-HK$0.01(-1.12%)
Day’s Range― - ―
52-Week RangeHK$0.33 - HK$0.78
Previous CloseN/A
Volume780.00K
Average Volume (3M)1.11M
Market Cap
HK$294.15M
Enterprise ValueHK$563.36
Total Cash (Recent Filing)HK$274.70M
Total Debt (Recent Filing)HK$434.05M
Price to Earnings (P/E)22.1
Beta0.33
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.54%
Share Statistics
EPS (TTM)0.02
Shares Outstanding622,499,940
10 Day Avg. Volume874,800
30 Day Avg. Volume1,111,766
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)0.44
Price to Sales (P/S)0.30
P/FCF Ratio4.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Established Pharmaceutical Distribution ModelA focused distribution business provides recurring revenue from wholesaling to pharmacies, hospitals and retail channels. Durable networks and channel relationships support repeat volumes and market access, making core sales less volatile and sustaining cash generation over multiple quarters.
Stable Gross Margins In Mid-to-high 20% RangeConsistent gross margins indicate resilient core product economics and purchasing/pricing stability. That stability cushions operating earnings against revenue swings, enabling margin recovery if operating costs are controlled and supporting long-term profitability if sales stabilize.
Positive Operating Cash Flow And Decent Cash ConversionPositive operating cash flow and reasonable conversion of accounting profits into FCF show the business generates cash to fund operations and dividends. While variable year-to-year, this cash conversion provides a foundation for shareholder returns and working-capital needs over the medium term.
Bears Say
Declining Revenue TrendA multi-year revenue decline erodes scale advantages in distribution, pressures bargaining power with suppliers, and increases per-unit fixed-cost burdens. If sales volumes do not recover, the company risks persistent margin compression and reduced ability to invest in growth or distribution expansion.
Sharply Deteriorating Profitability And Compressed ROEFalling net margins and a collapsing ROE reduce internal capital for reinvestment and make dividend maintenance harder without stronger cash flows. Structural profitability weakness can limit competitive reinvestment and heighten vulnerability to pricing or cost shocks over multiple quarters.
Rising Leverage And Cash Flow VolatilityHigher leverage combined with uneven free cash flow increases refinancing and interest-rate risk, reducing financial flexibility. During slower revenue periods, elevated debt levels constrain capital allocation, limit M&A or expansion choices, and raise the chance of covenant stress across the medium term.
Kingworld Medicines Group Ltd. News
1110 FAQ
What was Kingworld Medicines Group Ltd.’s price range in the past 12 months?
Kingworld Medicines Group Ltd. lowest stock price was HK$0.33 and its highest was HK$0.78 in the past 12 months.
What is Kingworld Medicines Group Ltd.’s market cap?
Kingworld Medicines Group Ltd.’s market cap is HK$294.15M.
When is Kingworld Medicines Group Ltd.’s upcoming earnings report date?
Kingworld Medicines Group Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 18 days.
How were Kingworld Medicines Group Ltd.’s earnings last quarter?
Kingworld Medicines Group Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.031 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kingworld Medicines Group Ltd. overvalued?
According to Wall Street analysts Kingworld Medicines Group Ltd.’s price is currently Overvalued.
Does Kingworld Medicines Group Ltd. pay dividends?
Kingworld Medicines Group Ltd. pays a Annually dividend of HK$0.032 which represents an annual dividend yield of 6.54%. See more information on Kingworld Medicines Group Ltd. dividends here
What is Kingworld Medicines Group Ltd.’s EPS estimate?
Kingworld Medicines Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kingworld Medicines Group Ltd. have?
Kingworld Medicines Group Ltd. has 622,499,940 shares outstanding.
What happened to Kingworld Medicines Group Ltd.’s price movement after its last earnings report?
Kingworld Medicines Group Ltd. reported an EPS of HK$0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kingworld Medicines Group Ltd.?
Currently, no hedge funds are holding shares in HK:1110
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kingworld Medicines Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.19%
12-Months-Change
Fundamentals
Return on Equity
6.54%
Trailing 12-Months
Asset Growth
6.64%
Trailing 12-Months
Company Description
Kingworld Medicines Group Ltd.
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―